Table 3.
Results of the multiple regression analyses: EORTC QLQ-C30 subscales (95 % confidence interval)
| Parameter | Global Health Status/QoL | Physical Functioning | Social Functioning | Fatigue |
|---|---|---|---|---|
| Symptom group | ||||
| Mildly symptomatic vs. asymptomatic | −8.04 (−19.42; 3.35) | −11.44 (−22.59; −0.29)* | −6.47 (−22.46; 9.51) | NS |
| Moderately symptomatic vs. asymptomatic | −11.66 (−23.93; 0.60) | −13.47 (−25.79; −1.16)* | −23.77 (−40.05; −7.50)* | NS |
| Severely symptomatic vs. asymptomatic | −19.11 (−32.43; −5.79)* | −23.68 (−37.30; −10.06)* | −33.95 (−51.10; −16.80)* | NS |
| Bone pain | ||||
| Moderate vs. mild/none | NAb | −10.50 (−20.04; −0.95)* | NS | NAb |
| Severe vs. mild/none | NAb | −18.37 (−32.26; −4.48)* | NS | NAb |
| Severe vs. moderate/mild/none | −21.32 (−34.69; −7.95)* | NA | NS | 22.62 (10.27; 34.98)* |
| Bone fracture: yes vs. no | NS | −14.53 (−25.87; −3.20)* | −15.06 (−31.41; 1.28) | NS |
| Fatigue (moderate vs. none/mild) | −10.95 (−19.64; −2.25)* | −14.00 (−22.52; −5.49)* | NS | 21.92 (13.14; 30.70)* |
| Infection (moderate/severe vs. mild/none) | NS | −21.54 (−35.52; −7.55)* | NS | NS |
| Dizziness (yes vs. no) | NS | NS | −15.13 (−27.40; −2.86)* | 11.75 (1.99; 21.51)* |
| Depression (yes vs. no) | −10.87 (−20.65; −1.09)* | NS | NS | NS |
| Mental status changes (yes vs. no) | NS | NS | −21.83 (−45.50; 1.84) | NS |
| Nausea/vomiting | NS | NS | NS | 14.91 (3.64; 26.18)* |
| Sleepiness (yes vs. no) | NS | NS | NS | 9.51 (1.43; 17.59)* |
| MM disease duration | −0.95 (−1.85; −0.05)* | NS | NS | NS |
| British descent | NS | 8.25 (1.61; 14.89)* | NS | NS |
| Age | NS | −0.50 (−0.82; −0.18)* | NS | NS |
| Number of comorbidities | NS | NS | NS | 2.55 (0.36; 4.73)* |
| Prior bortezomiba treatment duration | NS | −0.09 (−0.14; −0.04)* | NS | NS |
| Currently on treatment (yes vs. no) | −9.49 (−16.16; −2.83)* | NS | NS | NS |
| Type of current treatment | ||||
| Bortezomib containing vs. none | NS | NS | NS | 10.56 (1.80; 19.33)* |
| Lenalidomide containing vs. none | NS | NS | NS | 14.56 (2.78; 26.34)* |
| Thalidomide containing vs. none | NS | NS | NS | 3.93 (−8.66; 16.52) |
| Alkylating agents containing/other vs. none | NS | NS | NS | 10.74 (−3.23; 24.71) |
MM multiple myeloma, QoL quality of life, NS not significant at 0.1 level (i.e., P value of >0.1), NA not applicable
*P value of <0.05
aPrior thalidomide or alkylating agents were nonsignificant; prior lenalidomide and other treatments were not tested due to very low sample size (n = 3 and n = 6, respectively)
bFor Global Health Status and Fatigue, severity of bone pain was grouped into severe vs. moderate/mild/none given that there were no statistically significant differences between moderate, mild, and no bone pain on these scales. For Physical Functioning, severity of bone pain was grouped into severe, moderate, and mild/none given that there were no statitistically significant differences in effect on physical functioning between mild and no bone pain